Home » Stocks » SNPX

Synaptogenix, Inc. (SNPX)

Stock Price: $10.22 USD -0.81 (-7.34%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $10.10 -0.12 (-1.17%) Jun 22, 7:40 PM
Market Cap 37.57M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 3.51M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $10.22
Previous Close $11.03
Change ($) -0.81
Change (%) -7.34%
Day's Open 11.00
Day's Range 9.38 - 11.70
Day's Volume 551,104
52-Week Range 6.25 - 12.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, June 14, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it h...

1 week ago - PRNewsWire

Synaptogenix Inc (NASDAQ: SNPX) has announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer's disease (AD). To dat...

1 week ago - Benzinga

NEW YORK, June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update ...

1 week ago - PRNewsWire

NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement f...

2 weeks ago - PRNewsWire

NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced today that it has b...

2 weeks ago - PRNewsWire

NEW YORK, May 19, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, announced that the Company's ...

1 month ago - PRNewsWire

NEW YORK, April 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative dis...

1 month ago - PRNewsWire

NEW YORK, April 1, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on...

2 months ago - PRNewsWire

NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it will...

3 months ago - PRNewsWire

NEW YORK, Feb. 12, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that Dr. Ala...

4 months ago - PRNewsWire

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (the "Company" or Synaptogenix) (OTCQX: SNPX), formerly Neurotrope Bioscience, Inc., announced today that it has entered into definitive securi...

5 months ago - PRNewsWire

About SNPX

Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior Uni... [Read more...]

Industry
Biotechnology
Founded
2012
Stock Exchange
NASDAQ
Ticker Symbol
SNPX
Full Company Profile

Financial Performance

Financial Statements